Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Jerald Radich, MD

Professor
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Disclosures

Jerald Radich, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; Cepheid; HTG Molecular Diagnostics, Inc.; Novartis; NuProbe USA, Inc.

Jorge E. Cortes, MD

Director, Georgia Cancer Center
Professor, Department of Medicine
Augusta University
Augusta, Georgia

Disclosures

Jorge E. Cortes, MD, has the following relevant financial relationships:
Consultant or advisor for: Novartis; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda
Research funding from: Novartis; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda

Editor

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC

Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia

Authors: Jerald Radich, MD; Jorge E. Cortes, MD
CME / ABIM MOC Released: 3/20/2023
Valid for credit through: 3/20/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.50 ABIM MOC points

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists and other healthcare providers (HCPs) involved in the care of patients with CML.

The goal of this activity is for learners to be better able to create customized care plans incorporating approved TKIs for patients with CML, including patients with relapsed/refractory disease.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data for current CML treatment strategies
Have greater competence related to
- Individualizing treatment for patients with CML
Demonstrate greater confidence in their ability to
- Integrate recent clinical trial data into the treatment paradigm for patients with CML

Disclosures

Faculty

Jerald Radich, MD

Professor
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Disclosures

Jerald Radich, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen Inc.; Cepheid; HTG Molecular Diagnostics, Inc.; Novartis; NuProbe USA, Inc.

Jorge E. Cortes, MD

Director, Georgia Cancer Center
Professor, Department of Medicine
Augusta University
Augusta, Georgia

Disclosures

Jorge E. Cortes, MD, has the following relevant financial relationships:
Consultant or advisor for: Novartis; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda
Research funding from: Novartis; Pfizer Inc.; Sun Pharmaceutical Industries, Ltd.; Takeda

Editor

Lisa Cockrell, PhD

Medical Education Director, Medscape, LLC

Disclosures

Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia

Authors: Jerald Radich, MD; Jorge E. Cortes, MDFaculty and Disclosures

CME / ABIM MOC Released: 3/20/2023

Valid for credit through: 3/20/2024, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Jerald Radich, MD

Jorge E. Cortes, MD

Editor

Lisa Cockrell, PhD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

CME / ABIM MOC

Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Jerald Radich, MD

Jorge E. Cortes, MD

Editor

Lisa Cockrell, PhD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia

Learning Feedback Questions